HCV Reinfection and Cure: How Retreatment and Harm Reduction Are Changing the Game
21 January 2026 0 Comments James McQueen

HCV Reinfection and Cure: How Retreatment and Harm Reduction Are Changing the Game

When you hear that hepatitis C can be cured in just 8 to 12 weeks, it sounds almost too good to be true. And for many, it is. But for others-especially people who still inject drugs, use methamphetamine, or live in unstable housing-getting cured is only the beginning. The real challenge? Staying cured. HCV reinfection isn’t rare. It’s happening right now, in cities and towns across the world, and it’s not because the drugs don’t work. It’s because the system hasn’t caught up.

Why HCV Keeps Coming Back

The hepatitis C virus (HCV) is no longer the death sentence it once was. Since direct-acting antivirals (DAAs) arrived in 2014, cure rates have jumped from under 50% to over 95%. Drugs like glecaprevir/pibrentasvir (Mavyret) and sofosbuvir/velpatasvir (Epclusa) wipe out the virus in most people, with few side effects and no needles involved. But cure doesn’t mean immunity. You can get HCV again-even after you’ve been cured.

Reinfection happens fastest in the first six months after treatment. The risk is highest among people under 30, those who still inject drugs, and people using methamphetamine. Studies show injecting drug users are more than three times as likely to get reinfected compared to those who don’t. And it’s not just about sharing needles. Contaminated cookers, filters, or even water can spread the virus. In some places, up to 40% of people who were cured of HCV end up infected again within two years.

Retreatment Works-If You Can Get It

Here’s the good news: if you get reinfected, you can be cured again. Just like the first time. The same drugs that worked before work again. The CDC, WHO, and leading liver specialists all agree: treat everyone, every time. No judgment. No waiting. No "you should’ve quit drugs first" rules.

For most reinfections, an 8-week course of glecaprevir/pibrentasvir is the go-to. It’s simple, effective, and well-tolerated. If you had a relapse-meaning the virus came back after treatment-doctors might add ribavirin or switch to sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for 12 weeks. Resistance testing is only needed for relapses, not reinfections. That’s important: if you got HCV again because you were exposed to the virus, you don’t need fancy tests. Just treat it.

And now, there’s a new option. In June 2025, the FDA approved Mavyret specifically for acute HCV infection-the first DAA ever approved for early-stage disease. In trials, it cured 96% of people in just 8 weeks. For someone who just got infected, this means faster, simpler care.

Even shorter treatments are being tested. The PURGE-C trial found that 4 weeks of glecaprevir/pibrentasvir cured 84% of people with very new HCV infections. That’s not quite as good as 8 weeks, but for someone who can’t make it back for follow-up visits, it’s life-changing. And here’s the kicker: if the 4-week treatment didn’t work, they could still be cured with a full 8-week course later. No damage done.

Harm Reduction Isn’t Optional-It’s Essential

You can’t cure your way out of an epidemic if the conditions that spread the virus are still there. That’s why harm reduction isn’t a side note-it’s the backbone of real progress.

Needle and syringe programs (NSPs) that give out at least 200 clean needles per person per year cut HCV transmission by more than half. Methadone and buprenorphine (opioid agonist therapy) reduce new infections by 50%. These aren’t just "nice to have" services. They’re proven, cost-effective, and life-saving.

Yet, in many places, people are turned away from HCV treatment because they’re still using drugs. A 2024 survey of over 1,200 people who inject drugs found 68% had been denied care because of their drug use. That’s not just cruel-it’s counterproductive. Every time someone is denied treatment, the virus spreads further.

The best results come from integrated care. In Boston, clinics that offered HCV treatment the same day as opioid agonist therapy saw 82% of patients stick with treatment. In San Francisco, people who had to jump between addiction clinics and liver specialists often dropped out. When care is split, people fall through the cracks.

Person protected by clean syringes and harm reduction tools as virus fades away

What Comes After the Cure

Getting cured doesn’t mean you’re done. Your immune system doesn’t bounce back fully. Studies show T-cells-your body’s virus-fighting soldiers-stay partially exhausted even after the virus is gone. That’s why you’re still vulnerable to reinfection. Your body doesn’t remember how to fight HCV the way it does with vaccines like hepatitis B or measles.

That’s why surveillance matters. If you’re at risk, get tested every 3 months for the first 6 months after treatment. A simple blood test for HCV RNA can catch reinfection early. And if it comes back, treat it again. No stigma. No delay.

Also, don’t forget hepatitis B. Before starting any HCV treatment, you must be tested for HBV. If you have both, treating HCV can trigger a dangerous flare-up of hepatitis B. Between 2019 and 2024, the FDA recorded 12 cases of HBV reactivation linked to DAA treatment. It’s rare, but it’s preventable.

The Big Picture: Can We Really Eliminate HCV?

The World Health Organization wants to eliminate HCV as a public health threat by 2030. That means cutting new infections by 90% and reducing deaths by 65%. Right now, 58 million people live with HCV. About 1.5 million get infected every year.

The tools are here. We have the drugs. We have the harm reduction strategies. We have the data. But only 38% of countries offer needle programs at the level needed. In the U.S., only 32 states now allow same-day HCV treatment for people who inject drugs. The rest still require sobriety, housing, or paperwork before care.

The math is simple: if we treat fewer than 15% of eligible people each year and don’t expand needle programs to cover over 60% of people who inject drugs, we won’t hit the 2030 goal. And if we keep turning people away because of their drug use, we’re not just failing them-we’re letting the virus spread.

Three cartoon figures showing HCV stages from illness to cure to retreat with medical icons

What You Can Do

If you’ve been cured of HCV and still use drugs:

  • Get tested every 3 months for the first 6 months after treatment.
  • Use clean needles every time. If you can’t access a needle program, never reuse or share.
  • Ask for opioid agonist therapy if you use opioids. It helps your liver and your life.
  • If you get HCV again, don’t give up. Treat it again. It still works.
If you’re a clinician or service provider:

  • Treat everyone, every time. No exceptions.
  • Offer same-day HCV treatment. Don’t wait for sobriety.
  • Co-locate HCV care with addiction services. One stop. One team.
  • Don’t ask about drug use before offering treatment. Just offer it.

It’s Not About Perfection. It’s About Progress.

Some people say, "Why treat someone who might get infected again?" That’s like saying, "Why treat someone with diabetes if they’ll keep eating sugar?" Treatment isn’t about controlling behavior. It’s about saving lives.

HCV reinfection isn’t a failure of medicine. It’s a failure of policy. We have the cure. What we’re missing is the will to make sure everyone can access it-without shame, without delay, without conditions.

The next time someone says, "They’re just going to get it again," ask them this: What’s the alternative? Let them die? Let them spread it to others? Or treat them-and keep treating them-until the virus is gone for good?

The science says we can end HCV. The question now is: do we have the courage to do what it takes?